Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Moors & Cabot Inc.

Moors & Cabot Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 718 shares of the biopharmaceutical company’s stock after selling 127 shares during the period. Moors & Cabot Inc.’s holdings in Regeneron Pharmaceuticals were worth $377,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Activest Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Saudi Central Bank acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $31,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.02% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on REGN shares. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 target price on the stock. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $796.57.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $657.53 on Friday. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $588.03 and a 200 day moving average price of $568.04. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $834.42. The stock has a market cap of $69.69 billion, a P/E ratio of 15.75, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the company posted $12.46 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.